4-[(3,4-Dimethyl-5-nitrophenyl)sulfonyl]morpholine | 853752-29-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(3,4-Dimethyl-5-nitrophenyl)sulfonyl]morpholine
• 英文别名: 4-(3,4-dimethyl-5-nitrophenyl)sulfonylmorpholine
• CAS: 853752-29-1
• 化学式: C₁₂H₁₆N₂O₅S
• 分子量: 300.335
• InChiKey: RTFUYLBITFDBHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[(3,4-Dimethyl-5-nitrophenyl)sulfonyl]morpholine 在 水 、 铁粉 、 氯化铵 作用下， 以 乙醇 为溶剂， 以100%的产率得到2,3-Dimethyl-5-morpholin-4-ylsulfonylaniline
  参考文献：
  名称：

  Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability

  摘要：

  A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB2 agonists was conducted to improve the in vitro metabolic stability pro. le in this series while retaining high potency and selectivity for the CB2 receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB2 agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.062
• 作为产物：
  描述：

  吗啉 、 3,4-dimethyl-5-nitro-benzenesulfonyl chloride 以 乙酸乙酯 为溶剂， 以94%的产率得到4-[(3,4-Dimethyl-5-nitrophenyl)sulfonyl]morpholine
  参考文献：
  名称：

  Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability

  摘要：

  A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB2 agonists was conducted to improve the in vitro metabolic stability pro. le in this series while retaining high potency and selectivity for the CB2 receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB2 agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.10.062

文献信息

• Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability
  作者：Ian Sellitto、Bertrand Le Bourdonnec、Karin Worm、Allan Goodman、Markku A. Savolainen、Guo-Hua Chu、Christopher W. Ajello、Christopher T. Saeui、Lara K. Leister、Joel A. Cassel、Robert N. DeHaven、Christopher J. LaBuda、Michael Koblish、Patrick J. Little、Bernice L. Brogdon、Steven A. Smith、Roland E. Dolle

  DOI：10.1016/j.bmcl.2009.10.062

  日期：2010.1

  A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB2 agonists was conducted to improve the in vitro metabolic stability pro. le in this series while retaining high potency and selectivity for the CB2 receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB2 agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain. (C) 2009 Elsevier Ltd. All rights reserved.